Literature DB >> 2657573

Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations.

W S Alexander1, O Bernard, S Cory, J M Adams.   

Abstract

Transgenic mice bearing c-myc driven by the immunoglobulin heavy chain enhancer (E mu) initially exhibit a preneoplastic lymphoproliferative syndrome from which clonal pre-B or B lymphomas develop at random. To investigate whether this transition involves the activation of oncogenes capable of transforming fibroblasts, we transfected DNA from 14 E mu-myc lymphomas into NIH3T3 cells and tested the tumorigenicity of the transfectants in nude mice. By this assay and subsequent direct analysis of the lymphoma mRNA by cDNA cloning or the polymerase chain reaction, two independent E mu-myc lymphomas were shown to contain an N-ras or a K-ras oncogene mutated at codon 61. When incorporated into a recombinant retrovirus, the mutant N-ras allele could collaborate with myc to transform preneoplastic E mu-myc bone marrow pre-B cells. These results indicate that spontaneous mutation of ras genes is one pathway to lymphomagenesis in E mu-myc mice but that many of the lymphomas arise in response to changes that do not register in fibroblasts.

Entities:  

Mesh:

Year:  1989        PMID: 2657573

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

Review 1.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis.

Authors:  M W Gramling; C M Eischen
Journal:  Cell Death Differ       Date:  2012-02-03       Impact factor: 15.828

3.  bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA.

Authors:  W Tam; D Ben-Yehuda; W S Hayward
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

4.  Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.

Authors:  Cassandra J Vandenberg; Paul Waring; Andreas Strasser; Suzanne Cory
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

Review 5.  Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.

Authors:  Chenguang Wang; Michael P Lisanti; D Joshua Liao
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

6.  Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells.

Authors:  Masao Nakagawa; Shinobu Tsuzuki; Keiichiro Honma; Osamu Taguchi; Masao Seto
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

7.  Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.

Authors:  Michael A Linden; Nicole Kirchhof; Cathy S Carlson; Brian G Van Ness
Journal:  Exp Hematol       Date:  2011-11-23       Impact factor: 3.084

8.  Scribble acts as an oncogene in Eμ-myc-driven lymphoma.

Authors:  E D Hawkins; J Oliaro; K M Ramsbottom; A Newbold; P O Humbert; R W Johnstone; S M Russell
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

9.  Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.

Authors:  Seiichi Mori; Rachel E Rempel; Jeffrey T Chang; Guang Yao; Anand S Lagoo; Anil Potti; Andrea Bild; Joseph R Nevins
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

10.  Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.

Authors:  Hai Vu Nguyen; Cassandra J Vandenberg; Ashley P Ng; Mikara R Robati; Natasha S Anstee; Joel Rimes; Edwin D Hawkins; Suzanne Cory
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.